BOLT

Bolt Biotherapeutics, Inc. BOLT

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,861 of 2,925

Why it scores 11Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$5.0K

Quarter to Jun 30

Net income

$-7.72M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.31M total
Sofinnova Ventures Inc
$530.2K0.0%
RENAISSANCE TECHNOLOGIES LLC
$379.7K+27.7%
Vivo Capital, LLC
$278.8K0.0%
CITADEL ADVISORS LLC
$219.1K+462.9%
T3 Companies, LLC
$146.3K0.0%
Board of Trustees of The Leland Stanford Junior University
$138.5K0.0%
PFIZER INC
$133.8K0.0%
Lynx1 Capital Management LP
$118.6K0.0%
NANO CAP NEW MILLENNIUM GROWTH FUND L P
$105.9K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$73.6K-33.6%
Shay Capital LLC
$59.4K+3.6%
BlackRock, Inc.
$37.4K0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$27.2K0.0%
Nan Fung Group Holdings Ltd
$19.3K-82.9%
MORGAN STANLEY
$12.1K-1.4%
VANGUARD FIDUCIARY TRUST CO
$11.9K0.0%
NewEdge Advisors, LLC
$9.7KNew
Tower Research Capital LLC (TRC)
$6.6K+56.5%
UBS Group AG
$982-67.6%
SBI Securities Co., Ltd.
$501+1200.0%
JPMORGAN CHASE & CO
$1650.0%
CITIGROUP INC
$158New
BARCLAYS PLC
$230.0%
See all 23 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BOLT

Earnings Per Share

13fpro.ai/company/BOLT

Loading ratio trend…

BOLT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Bolt Biotherapeutics, Inc. (BOLT): stock profile, AI score and financials

Bolt Biotherapeutics, Inc. (BOLT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BOLT at 11.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,861 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Bolt Biotherapeutics, Inc. reports quarterly revenue of $5.0K, net income of $-7.7M. Top institutional holders of BOLT by reported 13-F value include Sofinnova Ventures, RENAISSANCE TECHNOLOGIES, Vivo Capital, based on the most recent SEC filings. BOLT trades on the Nasdaq exchange and files with the SEC under CIK 1641281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bolt Biotherapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1641281 →